Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their clinical benefit to more patients, a novel therapy to induce positive conversion in T790M-negative patients may be possible. We retrospective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Hata, Akito, Katakami, Nobuyuki, Kaji, Reiko, Yokoyama, Toshihide, Kaneda, Toshihiko, Tamiya, Motohiro, Inoue, Takako, Kimura, Hiromi, Yano, Yukihiro, Tamura, Daisuke, Morita, Satoshi, Negoro, Shunichi
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205165/
https://ncbi.nlm.nih.gov/pubmed/30410675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26192
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge